Results 241 to 250 of about 531,375 (310)

Long‐term impact of Elexacaftor/Tezacaftor/ivacaftor on pulmonary, nutritional and metabolic outcomes in homozygous F508del cystic fibrosis patients: A real‐world cohort study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Elexacaftor/tezacaftor/ivacaftor (ETI) has markedly improved cystic fibrosis (CF) outcomes. However, its long‐term impact on nutrition, metabolism and liver health remains underexplored. We assessed 30‐month changes in pulmonary, nutritional, metabolic and inflammatory markers in people with CF (PwCF) homozygous for F508del.
Nicola Perrotta   +5 more
wiley   +1 more source

How to bring generative AI to oncology practice. [PDF]

open access: yesESMO Real World Data Digit Oncol
Truhn D, Kather JN.
europepmc   +1 more source

Six solutions for clinical study data sharing in Germany. [PDF]

open access: yesBMC Med Res Methodol
Bobrov E   +4 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy